Welcome to our dedicated page for Xenon Pharmaceuticals news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceuticals stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals (XENE) plans to present at the Wells Fargo Healthcare Conference in Boston, MA, via a fireside chat scheduled for Wednesday, September 9, from 11:00 to 11:30 am ET.
Details and a live webcast link will be available in the Investors section of Xenon’s website, with a replay posted after the event, subject to possible schedule changes.
Xenon Pharmaceuticals (Nasdaq: XENE) granted equity inducement awards to five new non-officer employees under Nasdaq Listing Rule 5635(c)(4), effective August 27, 2026. The awards consist of an aggregate of 13,450 share options and 7,850 restricted share units (RSUs), approved by the board’s Compensation Committee.
The options have a $61.93 exercise price, equal to the August 27, 2026 closing price, a 10-year term, and vest over four years (25% at one year, then monthly thereafter). RSUs vest 25% annually over four years. All grants are made under the Amended and Restated 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) will present six data sets at the 16th European Epilepsy Congress (EEC) in Athens, Greece, on September 5-9, 2026. The program includes an oral presentation of topline Phase 3 X-TOLE2 efficacy and safety results for azetukalner in adults with focal onset seizures, plus multiple posters from the ongoing 7‑year X‑TOLE open-label extension covering ≥48‑month safety, long-term seizure reduction, and seizure freedom.
Additional posters will detail azetukalner’s KV7 binding, enhanced channel opening, and rational polytherapy potential, including in vivo data on additive effects with commonly prescribed antiseizure medications. Xenon will also present burden-of-illness research, early-stage NaV1.1 modulator XPC-A data in Dravet mice, and host Booth #9 and a Scientific Exhibit during EEC 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) reported Q2 2026 results and a broad clinical update. The company reaffirmed plans to submit a New Drug Application for azetukalner in focal onset seizures in Q3 2026 following a pre-NDA meeting with the FDA. Phase 3 X-TOLE3 (FOS) and X-ACKT (PGTCS) enrollment is ongoing, and multiple Phase 3 neuropsychiatry studies continue, with topline X-NOVA2 MDD data expected in H1 2027.
According to Xenon, cash, cash equivalents and marketable securities totaled $1.25 billion on June 30, 2026, providing a cash runway into 2029. Q2 2026 had no revenue, research and development expenses of $99.2 million, general and administrative expenses of $23.9 million, other income of $11.8 million, and a net loss of $110.7 million, or $(1.11) per share.
Xenon Pharmaceuticals (Nasdaq: XENE) reported that its Board Compensation Committee approved equity inducement grants for eleven new non-officer employees, effective July 30, 2026, under Nasdaq Listing Rule 5635(c)(4). The grants comprise an aggregate of 32,758 share options and 19,013 restricted share units (RSUs).
The options have a 10-year term and an exercise price of $64.19 per common share, equal to Xenon’s July 30, 2026 closing price. Options vest over four years, with 25% after one year from each employee’s start date and the remainder monthly. RSUs vest 25% annually over four years from the July 30, 2026 grant date. Both awards are issued under Xenon’s Amended and Restated 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q2 2026 financial results and provide a business update after the close of U.S. markets on Thursday, August 6, 2026, followed by a company presentation at 4:30 p.m. ET (1:30 p.m. PT).
Investors can access the event via live webcast on the Investors section of Xenon’s website or by dialing (800) 715-9871 (toll-free) or (646) 307-1963 (international), using conference ID 5286122. According to Xenon Pharmaceuticals, a replay will be posted after the event and the timing is subject to change.
Xenon Pharmaceuticals (Nasdaq:XENE) granted equity inducement awards to four new non-officer employees under Nasdaq Listing Rule 5635(c)(4). The grants include 20,200 share options at $60.30 and 11,850 RSUs, with four-year vesting schedules and 10-year option terms.
Xenon also highlights its lead molecule azetukalner, a KV7 potassium channel opener in Phase 3 trials for epilepsy, MDD, and BPD, plus early-stage KV7 and NaV1.7 pain programs.
Xenon Pharmaceuticals (Nasdaq:XENE) granted equity inducement awards to 10 new non-officer employees under Nasdaq Listing Rule 5635(c)(4). Grants, effective May 28, 2026, include 32,750 share options at an exercise price of $54.79 and 19,200 RSUs, all under Xenon’s 2025 Inducement Equity Incentive Plan.
Options vest over four years with a 10-year term; RSUs vest in four equal annual installments. Xenon is a neuroscience-focused biopharma with lead KV7 opener azetukalner in Phase 3 trials for epilepsy, MDD, and BPD, plus early-stage potassium and sodium channel programs.
Xenon (Nasdaq: XENE) reported Q1 2026 results and a business update on May 7, 2026. Key points: positive Phase 3 X-TOLE2 topline for azetukalner (25 mg MPC -53.2%; placebo-adjusted -42.7%), planned NDA submission in Q3 2026, cash and marketable securities of $1.34B supporting runway into 2029, and Q1 net loss of $102.3M. Multiple Phase 3 studies and Phase 1 pain programs continue; X-NOVA2 MDD topline expected H1 2027. Conference call held 4:30 pm ET on May 7, 2026.
Xenon Pharmaceuticals (Nasdaq: XENE) announced inducement equity grants to seven new non-officer employees comprising an aggregate of 25,600 share options and 15,000 restricted share units (RSUs), effective April 30, 2026, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The share options carry a $56.04 exercise price, vest over four years, have a 10-year term, and RSUs vest 25% annually over four years, all subject to the company’s inducement equity incentive plan and continued service requirements.